{"id":"W3165082155","doi":"10.1136/annrheumdis-2021-eular.106","title":"POS0895 EFFECT OF TOFACITINIB ON PATIENT-REPORTED OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 3 TRIAL","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Fibromyalgia and Chronic Fatigue Syndrome Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pfizer (Canada)","funders":"Celgene; Gilead Sciences; Pfizer; Eli Lilly and Company","keywords":"Tofacitinib; Medicine; Ankylosing spondylitis; Physical therapy; Internal medicine; Janus kinase inhibitor; Quality of life (healthcare); Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001516652,0.001670245,0.00250047,0.0003198305,0.0004227707,0.00132695,0.0008008544,0.001666135,0.005636743],"category_scores_gemma":[0.001529051,0.0003919583,0.00382369,0.0004748896,0.0008698318,0.001348086,0.0003237197,0.004678368,0.001266674],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000839944,"about_ca_system_score_gemma":0.0007961365,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007476848,"about_ca_topic_score_gemma":0.002062469,"domain_scores_codex":[0.9995213,0.0001901691,0.00003565439,0.00008960786,0.00005843586,0.0001050231],"domain_scores_gemma":[0.9991736,0.000265473,0.0002070724,0.0000552176,0.00006249383,0.0002361067],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8618115,0.006463459,0.005853394,0.002024326,0.007315078,0.0002332865,0.0001441037,0.002190803,0.006613562,0.0004404065,0.008432874,0.0984773],"study_design_scores_gemma":[0.8513371,0.1174764,0.02146835,0.0001912631,0.002933746,0.0003524093,0.0001113209,0.001154808,0.0007124885,0.0006175369,0.003570817,0.0000737042],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9714673,0.01755289,0.0003566213,0.001610061,0.0007111602,0.0005932818,0.003067098,0.0001955898,0.004445975],"genre_scores_gemma":[0.9853699,0.005046556,0.0006536084,0.002049578,0.0004980211,0.0007988512,0.003689466,0.00002919745,0.001864715],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005636743,"threshold_uncertainty_score":0.01885682,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03138855147861491,"score_gpt":0.3395980626660912,"score_spread":0.3082095111874762,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}